Clinical trials: Recurrent Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and saliva from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898300
- Testing
- biologic sample preservation procedure, biopsy
- Where
- 98 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Radiation Therapy Oncology Group
HNSCC, Head and Neck Neoplasms
A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy
Open, multicenter, single arm, phase II, biomarker driven umbrella trial for head and neck squamous cell carcinoma (FGFR inhibitor, CDK4/6 inhibitor, pan HER inhibitor, PI3K inhibitor, PD1/PD-L1 inhibitor)
- Trial name
- NCT03356587
- Testing
- Abemaciclib
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Seoul National University Hospital
Head and Neck Neoplasms, Recurrent Disease
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell…
- Conditions
- Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
- Trial name
- NCT05260671
- Testing
- Penpulimab combined with cetuximab
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT01064921
- Testing
- vorinostat, cisplatin, radiation therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC
A single-arm phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status of 2 with recurrent or metastatic squamous cell carcinoma of the head and neck.
- Trial name
- POPPY (NCT03813836)
- Testing
- Pembrolizumab
- Where
- 12 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- University College, London
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck
Phase I trial to study the effectiveness of intratumoral (in the tumor) PV701 in treating patients who have advanced or recurrent unresectable squamous cell carcinoma (cancer) of the head and neck.
- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00081211
- Testing
- PV701
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
This phase II trial is studying how well giving carboplatin, paclitaxel, cetuximab, and erlotinib hydrochloride together works in treating patients with metastatic or recurrent squamous cell head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01316757
- Testing
- cetuximab, paclitaxel, carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Fox Chase Cancer Center
Head and Neck Neoplasms
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
This study will test an investigational study drug called patritumab. It is a 'randomized study' which means participants have an equal chance of being assigned to receive the experimental medication (patritumab) or a substance…
- Trial name
- NCT02633800
- Testing
- Patritumab, Cetuximab, Cisplatin
- Where
- 34 sites in Belgium, France and 5 more
- Volunteers
- 87 people
- Sponsor
- Daiichi Sankyo
Head and Neck Squamous Cell Carcinoma, Oncolytic Virus
H101 Plus TACE for r/m HNSCC
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
- Trial name
- NCT07398664
- Testing
- H101, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Head and Neck Squamous Cell Carcinoma, Skin Cancer
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT05047094
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembrolizumab
- Where
- 3 sites in Israel
- Volunteers
- 48 people
- Sponsor
- Alpha Tau Medical LTD.
Head and Neck Cancer
Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00589186
- Testing
- Ad5F35-LMP1/LMP2-transduced autologous dendritic cells, celecoxib, flow cytometry
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National Cancer Centre, Singapore
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and…
- Trial name
- NCT04868162
- Testing
- MRG003, MRG003+HX008
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Head and Neck Cancer
A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma
This is an open-label phase II, multicenter study. Eligible patients will receive CP-751,871 in monotherapy (20 mg/kg IV infusion on Day 1 of 3-week cycles). Tumor check-up will be performed every 6-8 weeks.
- Trial name
- NCT00872404
- Testing
- CP-751,871
- Where
- 2 sites in Belgium
- Volunteers
- 37 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Head and Neck Squamous Cell Carcinoma
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed…
- Trial name
- STELLAR-305 (NCT06082167)
- Testing
- Zanzalintinib, Pembrolizumab
- Where
- 168 sites in United States, Argentina and 24 more
- Volunteers
- 600 people
- Sponsor
- Exelixis
Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
This is a Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck, Metastasis, Recurrence
- Trial name
- NCT03799744
- Testing
- VCN-01, Durvalumab
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Institut Català d'Oncologia
Head And Neck Cancer
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
The goal of this clinical research study is to learn if RAD001 in combination with Tarceva (erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC).
- Trial name
- NCT00942734
- Testing
- Erlotinib, RAD001
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic…
- Trial name
- KEYNOTE-B84 (NCT04815720)
- Testing
- pepinemab + pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vaccinex Inc.
Head and Neck Squamous Cell Carcinoma
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
CX1106 is a novel inhibitor of thymidylate synthase (TS) developed as a potential antitumor agent by virtue of the rate limiting role of TS in the biosynthesis of thymidine.
- Trial name
- HNSCC (NCT04093115)
- Testing
- CX1106
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Breast Cancer, Head and Neck Cancer
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphedema
- Trial name
- AMWELL-SL (NCT00828516)
- Testing
- Acupuncture and moxibustion
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- East and North Hertfordshire NHS Trust
Oral Squamous Cell Carcinoma
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
The research and development of novel anti-tumor agents in oral cancer is slow, the investigation of repositioning use of currently available drugs in clinical, such as a selective cyclooxygenase-2 (COX-2) inhibitor…
- Trial name
- NCT02739204
- Testing
- Celecoxib
- Where
- Taiwan
- Volunteers
- 270 people
- Sponsor
- China Medical University Hospital